Understanding Adakveo®
Adakveo® (crizanlizumab-tmca) is a prescription medication used in people 16 years and older with sickle cell disease (SCD) to help reduce the frequency of painful vaso-occlusive crises (VOCs)—painful episodes caused by sickled red blood cells blocking blood flow.
Adakveo® works by binding to P-selectin, a protein that contributes to the cellular interactions leading to vaso-occlusion. By targeting P-selectin, Adakveo® helps prevent red blood cells from sticking together and blocking small blood vessels, thereby reducing the frequency and severity of VOCs.
How Adakveo® Works:
- Reduces the frequency of vaso-occlusive crises (VOCs) by approximately 45% in clinical trials.
- Helps decrease pain episodes and hospitalizations associated with sickle cell disease.
- Targets the root cause of vaso-occlusion, improving blood flow and reducing complications.
FDA Approval:
- Approved for the prevention of vaso-occlusive crises (VOCs) in sickle cell disease.
For more information, please visit the Adakveo® patient website. Some browsers may reroute this link to the Prescribing Information. Speak with your healthcare provider to determine if Adakveo® is the right treatment option for you.
